AFT Pharmaceuticals (NZSE:AFT) Beneish M-Score: -1.85 (As of Jul. 12, 2026)


NZSE:AFT AFT Pharmaceuticals Ltd NZSE:AFT
95 GF Score
Price NZ$3.91
GF Value NZ$4.18
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is AFT Pharmaceuticals Beneish M-Score?

AFT Pharmaceuticals NZSE:AFT 95 Beneish M-Score is -1.85 as of Jul. 12, 2026. GuruFocus rates NZSE:AFT with a GF Score™ of 95/100 and a GF Value™ of NZ$4.18 (Fairly Valued). The stock has 4 warning signs investors should review. Among 911 Drug Manufacturers companies, AFT Pharmaceuticals ranks worse than 83.53% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -1.85 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for AFT Pharmaceuticals's Beneish M-Score or its related term are showing as below:

NZSE:AFT' s Beneish M-Score Range Over the Past 10 Years
Min: -2.8   Med: -2.28   Max: -1.85
Current: -1.85

During the past 11 years, the highest Beneish M-Score of AFT Pharmaceuticals was -1.85. The lowest was -2.80. And the median was -2.28.


AFT Pharmaceuticals Beneish M-Score Historical Data

* Premium members only.

The historical data trend for AFT Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AFT Pharmaceuticals Beneish M-Score Chart

AFT Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.21 -2.28 -2.80 -2.54 -1.85

AFT Pharmaceuticals Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.80 0.00 -2.54 0.00 -1.85

NZSE:AFT vs ZTS, UTHR, VTRS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AFT Pharmaceuticals Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where AFT Pharmaceuticals's Beneish M-Score falls into.


NZSE:AFT
95GF Score
AFT Pharmaceuticals Ltd NZSE:AFT
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AFT Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of AFT Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1008+0.528 * 1.0185+0.404 * 0.875+0.892 * 1.2224+0.115 * 0.8608
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.964+4.679 * 0.095655-0.327 * 1.1823
=-1.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was NZ$58.1 Mil.
Revenue was NZ$251.2 Mil.
Gross Profit was NZ$107.0 Mil.
Total Current Assets was NZ$148.5 Mil.
Total Assets was NZ$217.0 Mil.
Property, Plant and Equipment(Net PPE) was NZ$3.4 Mil.
Depreciation, Depletion and Amortization(DDA) was NZ$3.7 Mil.
Selling, General, & Admin. Expense(SGA) was NZ$74.6 Mil.
Total Current Liabilities was NZ$66.3 Mil.
Long-Term Debt & Capital Lease Obligation was NZ$41.6 Mil.
Net Income was NZ$14.7 Mil.
Gross Profit was NZ$3.5 Mil.
Cash Flow from Operations was NZ$-9.5 Mil.
Total Receivables was NZ$43.2 Mil.
Revenue was NZ$205.5 Mil.
Gross Profit was NZ$89.2 Mil.
Total Current Assets was NZ$108.3 Mil.
Total Assets was NZ$169.8 Mil.
Property, Plant and Equipment(Net PPE) was NZ$3.3 Mil.
Depreciation, Depletion and Amortization(DDA) was NZ$2.7 Mil.
Selling, General, & Admin. Expense(SGA) was NZ$63.3 Mil.
Total Current Liabilities was NZ$43.3 Mil.
Long-Term Debt & Capital Lease Obligation was NZ$28.2 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(58.125 / 251.194) / (43.196 / 205.494)
=0.231395 / 0.210206
=1.1008

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(89.186 / 205.494) / (107.04 / 251.194)
=0.434008 / 0.426125
=1.0185

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (148.543 + 3.362) / 217.01) / (1 - (108.342 + 3.25) / 169.815)
=0.300009 / 0.342861
=0.875

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=251.194 / 205.494
=1.2224

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.669 / (2.669 + 3.25)) / (3.699 / (3.699 + 3.362))
=0.450921 / 0.523863
=0.8608

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(74.62 / 251.194) / (63.323 / 205.494)
=0.297061 / 0.30815
=0.964

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((41.594 + 66.347) / 217.01) / ((28.186 + 43.256) / 169.815)
=0.497401 / 0.420705
=1.1823

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(14.73 - 3.511 - -9.539) / 217.01
=0.095655

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

AFT Pharmaceuticals has a M-score of -1.85 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -1.85 mean?
AFT Pharmaceuticals (NZSE:AFT) has a Beneish M-Score of -1.85 as of Jul. 12, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on AFT Pharmaceuticals and its competitors. According to the industry distribution chart, AFT Pharmaceuticals ranks #761 out of 911 companies in the Drug Manufacturers industry, placing it in the top 83.5%.
Is AFT Pharmaceuticals' Beneish M-Score too high?
AFT Pharmaceuticals' current Beneish M-Score is -1.85. Based on the distribution chart, AFT Pharmaceuticals ranks #761 out of 911 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, AFT Pharmaceuticals has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AFT Pharmaceuticals ranks #761 out of 911 companies for Beneish M-Score. This places AFT Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on AFT Pharmaceuticals and its competitors. AFT Pharmaceuticals's current Beneish M-Score is -1.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (NZSE:AFT) is currently considered Fairly Valued. The stock's GF Value™ is NZ$4.18, compared to a current price of NZ$3.91 — trading 6.5% below its estimated fair value. The current Beneish M-Score is -1.85. AFT Pharmaceuticals' overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For AFT Pharmaceuticals (NZSE:AFT), the current Beneish M-Score is -1.85 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AFT Pharmaceuticals (NZSE:AFT) Overvalued in 2026?

Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be undervalued. The current stock price of NZ$3.91 is trading 6.5% below its estimated GF Value™ of NZ$4.18. GuruFocus considers AFT Pharmaceuticals to be Fairly Valued.

Key valuation signals for NZSE:AFT:

  • Beneish M-Score: -1.85
  • GF Value™: NZ$4.18 vs. price of NZ$3.91 (6.5% below fair value)
  • GF Score™: 95/100 with 4 warning signs

No single metric tells the full story. See the NZSE:AFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AFT Pharmaceuticals Business Description

Other Exchanges AFP:Australia
Address 129 Hurstmere Road, Level 1, Takapuna, Auckland, NTL, NZL, 0622
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
95GF Score

Get the complete analysis for NZSE:AFT

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NZ$3.91
Price
NZ$4.18
GF Value